piracetam has been researched along with Alcohol Drinking in 12 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Alcohol Drinking: Behaviors associated with the ingesting of ALCOHOLIC BEVERAGES, including social drinking.
Excerpt | Relevance | Reference |
---|---|---|
"Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 9.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
"Our data suggest that levetiracetam is not an appropriate treatment for non-treatment seeking alcohol abusers and can, in fact, increase their consumption of alcohol." | 5.16 | The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers. ( Coker, AR; Grossman, LE; Messing, RO; Mitchell, JM, 2012) |
"This study suggests that levetiracetam deserves further study in the treatment of alcohol dependence and co-occurring anxiety disorders." | 5.13 | Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review. ( Levin, FR; Mariani, JJ, 2008) |
" The increased risk associated with piracetam may reflect awareness of memory problems before any diagnosis of dementia has been made." | 3.75 | Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET. ( Beckett, N; Bulpitt, C; de Vernejoul, MC; Fletcher, A; Gainsborough, N; Geneva, M; Lu, FH; Peters, R; Poulter, R; Tzekova, M; Williams, B, 2009) |
"Zonisamide is a structurally related anticonvulsant that is a promising agent for the treatment of AD and may have greater tolerability than topiramate." | 2.80 | Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders. ( Ciraulo, DA; Colaneri, L; Devine, E; Knapp, CM; Oscar-Berman, M; Putnam, M; Richambault, C; Richardson, MA; Sarid-Segal, O; Streeter, CC; Surprise, C; Waters, M, 2015) |
"The findings of this study provide some evidence that levetiracetam is an efficacious and safe treatment option for outpatient alcohol detoxification." | 1.36 | Efficacy and safety of levetiracetam for outpatient alcohol detoxification. ( Förg, A; Heimann, HM; Hein, J; Heinz, A; Hinzpeter, A; Müller, CA; Schäfer, M; Schneider, S; Volkmar, K, 2010) |
"The enhanced seizure susceptibility after a single dose of ethanol was abolished by piracetam and MGO." | 1.27 | Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility. ( Andreas, K; Dienel, A; Schmidt, J, 1985) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (25.00) | 18.7374 |
1990's | 2 (16.67) | 18.2507 |
2000's | 2 (16.67) | 29.6817 |
2010's | 5 (41.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fish, EW | 1 |
Agoglia, AE | 1 |
Krouse, MC | 1 |
Muller, RG | 1 |
Robinson, JE | 1 |
Malanga, CJ | 1 |
Knapp, CM | 1 |
Ciraulo, DA | 1 |
Sarid-Segal, O | 1 |
Richardson, MA | 1 |
Devine, E | 1 |
Streeter, CC | 1 |
Oscar-Berman, M | 1 |
Surprise, C | 1 |
Colaneri, L | 1 |
Putnam, M | 1 |
Waters, M | 1 |
Richambault, C | 1 |
Mariani, JJ | 1 |
Levin, FR | 1 |
Peters, R | 1 |
Beckett, N | 1 |
Geneva, M | 1 |
Tzekova, M | 1 |
Lu, FH | 1 |
Poulter, R | 1 |
Gainsborough, N | 1 |
Williams, B | 1 |
de Vernejoul, MC | 1 |
Fletcher, A | 1 |
Bulpitt, C | 1 |
Müller, CA | 1 |
Schäfer, M | 1 |
Schneider, S | 1 |
Heimann, HM | 1 |
Hinzpeter, A | 1 |
Volkmar, K | 1 |
Förg, A | 1 |
Heinz, A | 1 |
Hein, J | 1 |
Zalewska-Kaszubska, J | 1 |
Bajer, B | 1 |
Czarnecka, E | 1 |
Dyr, W | 1 |
Gorska, D | 1 |
Mitchell, JM | 1 |
Grossman, LE | 1 |
Coker, AR | 1 |
Messing, RO | 1 |
Schmidt, J | 2 |
Andreas, K | 2 |
Dienel, A | 2 |
Fischer, HD | 1 |
Wustmann, C | 1 |
Genton, P | 1 |
Guerrini, R | 1 |
Salimov, RM | 1 |
Viglinskaia, IV | 1 |
Badian, M | 1 |
Brettel, HF | 1 |
Malerczyk, V | 1 |
Ostrowski, J | 1 |
Sittig, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Double-Blind, Placebo-Controlled, Parallel Group Design Trial of; Levetiracetam, Zonisamide, Topiramate, and Placebo Control for the Treatment of Alcohol Dependent Subjects.[NCT00862563] | Phase 2 | 85 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Recruitment goals could not be met before ending of funding for this project.) | ||
Placebo-Controlled Crossover Trial of Levetiracetam on Ethanol Intake[NCT01168687] | 46 participants (Actual) | Interventional | 2008-11-30 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Total Scores AB-Neurotoxicity Scale Week 12. This scale provides subject ratings of anticonvulsant neurotoxic effects. Scores may range 0 to 72, with possibility of an additional 30 points being for complaints not listed in the list of complaints provides. Total scores, therefore, may be as high as 102, with higher scores indicating greater severity of problems. Actual mean scores are shown. Means for the analysis are least means squares values obtained from a two-way repeated measures mixed models analysis, with Week (time) as the the within subject factor and treatment as the between group factor. Baseline values were used as covariates. (NCT00862563)
Timeframe: Week 12
Intervention | Scale Scores (Mean) |
---|---|
Zonisamide | 7.1 |
Levetiracetam | 11.3 |
Topiramate | 15.4 |
Sugar Pill | 5.8 |
Number of words generated that start with a set of 3 letters. The COWAT provides a measure of verbal fluency. Actual means for COWAT results are shown. (NCT00862563)
Timeframe: Baseline & Week 12
Intervention | Number of Words Produced (Mean) | |
---|---|---|
Baseline | Week 12 | |
Levetiracetam | 46.2 | 45.4 |
Sugar Pill | 47.4 | 50.5 |
Topiramate | 43.4 | 28.1 |
Zonisamide | 46.5 | 32.5 |
Number of words produced by subjects over 60 seconds for a semantic category (Animals). The COAWAT-Category sub-test provides a measure of verbal fluency. Mean value shown are actual means for the number of words produced. (NCT00862563)
Timeframe: Baseline, Week12
Intervention | Number of Words Produced (Mean) | |
---|---|---|
Baseline | Week 12 | |
Levetiracetam | 20.9 | 21.2 |
Sugar Pill | 21.6 | 20.8 |
Topiramate | 21.9 | 17.0 |
Zonisamide | 22.6 | 17.4 |
Mean weekly values for each treatment group for percent days heavy drinking. Heavy drinking was defined as 4 or more drinks per day for women and 5 or more drinks per day for men. (NCT00862563)
Timeframe: Weeks 10, 11, 12
Intervention | Percentage of Days/Week (Mean) | ||
---|---|---|---|
Week 10 | Week 11 | Week 12 | |
Levetiracetam | 49.6 | 47.9 | 44.5 |
Sugar Pill | 65.7 | 61.7 | 60.9 |
Topiramate | 32.1 | 29.5 | 21.0 |
Zonisamide | 38.4 | 36.6 | 34.3 |
Mean percent days drinking for Weeks 10, 11, 12. A drinking day is considered to be a day in which 1 or more drinks have been consumed. Means are model generated least means squares values obtained from a two-way repeated measures analysis from data obtained from Weeks 1 through 12, with Week as the within subject factor and treatment group as the between group factor. (NCT00862563)
Timeframe: Weeks 10, 11, 12
Intervention | Percentage of Days/ Week (Mean) | ||
---|---|---|---|
Week 10 | Week 11 | Week 12 | |
Levetiracetam | 72.2 | 68.9 | 73.1 |
Sugar Pill | 83.6 | 87.2 | 78.2 |
Topiramate | 51.8 | 43.8 | 51.4 |
Zonisamide | 61.6 | 62.1 | 61.3 |
Mean standard drinks consumed per day for each treatment week, weeks 10 thru 12. Actual mean values obtained are shown. Analyses are based on model generated least squares means for a two -way repeated measures mixed models analysis for data obtained for weeks 1 through 12, with baseline values used as covariates. Week (time) was used as the within subject factor and treatment group was the between group factor. (NCT00862563)
Timeframe: Weeks 10, 11, 12
Intervention | Standard Drinks per day (Mean) | ||
---|---|---|---|
Week 10 | Week 11 | Week 12 | |
Levetiracetam | 4.6 | 4.3 | 4.3 |
Sugar Pill | 6.3 | 6.8 | 6.0 |
Topiramate | 3.2 | 2.7 | 2.5 |
Zonisamide | 3.8 | 3.4 | 2.5 |
WMS Spatial Span test measures working memory for a spatial sequence of numbers. This assesses visual working memory. Age adjusted scaled scores are presented. Score may range between 1 and 19, with lower scores indicating greater impairment in performance. (NCT00862563)
Timeframe: Baseline, Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Week 12 | |
Levetiracetam | 10.5 | 10.9 |
Sugar Pill | 10.8 | 10.4 |
Topiramate | 12.0 | 8.4 |
Zonisamide | 10.8 | 7.9 |
WMS Digit Span is a measure of working memory. Subjects respond by repeating lists of number sequences presented by the test administrator. Age adjusted scores are presented below. Scores may range between 1 and 19, with lower scores indicating poorer performance on the task. (NCT00862563)
Timeframe: Baseline, Week 12
Intervention | units on a scale (Mean) | |
---|---|---|
Baseline | Week 12 | |
Levetiracetam | 11.9 | 12.2 |
Sugar Pill | 12.6 | 13.0 |
Topiramate | 12.1 | 7.7 |
Zonisamide | 11.8 | 10.0 |
The primary outcome of this study is to determine the effect of levetiracetam on alcohol consumption as measured by change in # of drinks during each treatment period. (NCT01168687)
Timeframe: During each 14 day treatment period
Intervention | number of drinks per treatment period (Mean) |
---|---|
All Subjects (n = 46) Placebo | 41.2 |
All Subjects (n = 46) Levetiracetam | 45.4 |
3 trials available for piracetam and Alcohol Drinking
Article | Year |
---|---|
Zonisamide, topiramate, and levetiracetam: efficacy and neuropsychological effects in alcohol use disorders.
Topics: Adult; Aged; Alcohol Drinking; Alcohol-Related Disorders; Anticonvulsants; Cognition Disorders; Doub | 2015 |
Levetiracetam for the treatment of co-occurring alcohol dependence and anxiety: case series and review.
Topics: Adult; Alcohol Drinking; Alcoholism; Anxiety Disorders; Diagnosis, Dual (Psychiatry); Female; Humans | 2008 |
The anticonvulsant levetiracetam potentiates alcohol consumption in non-treatment seeking alcohol abusers.
Topics: Alcohol Drinking; Alcoholism; Anticonvulsants; Cross-Over Studies; Dose-Response Relationship, Drug; | 2012 |
9 other studies available for piracetam and Alcohol Drinking
Article | Year |
---|---|
Levetiracetam results in increased and decreased alcohol drinking with different access procedures in C57BL/6J mice.
Topics: Alcohol Drinking; Animals; Anticonvulsants; Central Nervous System Depressants; Choice Behavior; Dos | 2014 |
Sociodemographic and lifestyle risk factors for incident dementia and cognitive decline in the HYVET.
Topics: Aged, 80 and over; Aging; Alcohol Drinking; Antihypertensive Agents; Cognition Disorders; Dementia; | 2009 |
Efficacy and safety of levetiracetam for outpatient alcohol detoxification.
Topics: Adolescent; Adult; Aged; Alcohol Drinking; Alcoholism; Ambulatory Care; Anticonvulsants; Female; Hum | 2010 |
Voluntary alcohol consumption and plasma beta-endorphin levels in alcohol preferring rats chronically treated with levetiracetam: a preliminary study.
Topics: Alcohol Drinking; Alcoholism; Animals; Anticonvulsants; beta-Endorphin; Disease Models, Animal; Dose | 2011 |
Ethanol preference behaviour and dopamine release in the rat.
Topics: Alcohol Drinking; Amphetamines; Animals; Behavior, Animal; Corpus Striatum; Dopamine; Food Preferenc | 1984 |
Effect of alcohol on action myoclonus in Lance-Adams syndrome and progressive myoclonus epilepsy.
Topics: Alcohol Drinking; Drug Tolerance; Epilepsies, Myoclonic; Follow-Up Studies; Humans; Myoclonus; Pirac | 1992 |
[Evaluation of accelerated development of stable alcoholic motivation in rats for studying potential alcohol deterrents].
Topics: Alcohol Deterrents; Alcohol Drinking; Alcoholism; Animals; Carbazoles; Ethanol; Male; Motivation; Pi | 1990 |
[Combination of alcohol and piracetam].
Topics: Adult; Alcohol Drinking; Arousal; Drug Interactions; Humans; Male; Piracetam; Postural Balance; Psyc | 1987 |
Influence of nootropic drugs on drinking behaviour in ethanol-preferring mice and ethanol-induced increase of seizure susceptibility.
Topics: Alcohol Drinking; Alcoholism; Animals; Dihydroergotoxine; Ethanol; Male; Meglumine; Mice; Mice, Inbr | 1985 |